NovoCure Limited Q4 2025 Earnings Call Summary

NovoCure Limited Q4 2025 Earnings Call Summary - Moby Strategic Execution and Operational Evolution Achieved record net revenue of $655 million in 2025, driven by substantial active patient growth in international markets like France and Japan. Transitioned to a multi-indication platform company following the FDA approval of Optune Pax for locally advanced pancreatic cancer in a record 180-day review cycle. Stabilized the core glioblastoma (GBM) business in mature markets, shifting focus toward high ...